Endocrinology, Vol 131, 2479-2481, Copyright © 1992 by Endocrine Society

ARTICLES

Somatostatin analog induces insulin-like growth factor binding protein- 1 (IGFBP-1) expression in human hepatoma cells

SG Ren, S Ezzat, S Melmed and GD Braunstein
Division of Endocrinology & Metabolism, Cedars-Sinai Medical Center- UCLA School of Medicine 90048.

As the somatostatin analog octreotide suppresses pituitary GH secretion and circulating IGF-1 levels, we examined its effects on human hepatoma (hep G2) cells which selectively express IGFBP-1. Octreotide (60 nM) stimulated IGFBP-1 up to 4.1-fold (p < 0.001 after 24 hrs). Induction of IGFBP-1 was first detectable after 12 hrs of 6 nM octreotide (1.5- fold, p < 0.03), and was confirmed by ligand blotting. Cholera toxin and forskolin induced IGFBP-1 independently and were also additive with octreotide. IGFBP-1 mRNA expression was induced 2.7-fold by octreotide. Thus, octreotide induces basal and stimulated IGFBP-1 in hepatocytes independently of insulin and GH. As IGFBP-1 may regulate peripheral IGF- 1 action, induction of IGFBP-1 represents a novel pituitary-independent mechanism for octreotide action.

This article has been cited by other articles:

				H Reynaert, K Rombouts, A Vandermonde, D Urbain, U Kumar, P Bioulac-Sage, M Pinzani, J Rosenbaum, and A Geerts Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma Gut, August 1, 2004; 53(8): 1180 - 1189. [Abstract] [Full Text] [PDF]

				K. Pistevou-Gombaki, N. Eleftheriadis, G. A Plataniotis, I. Sofroniadis, and V. E Kouloulias Octreotide for palliative treatment of hepatic metastases from non-neuroendocrine primary tumours: evaluation of quality of life using the EORTC QLQ-C30 questionnaire Palliative Medicine, April 1, 2003; 17(3): 257 - 262. [Abstract] [PDF]

				K Saito, S Inoue, T Saito, S Kiso, N Ito, S Tamura, H Watanabe, H Takeda, H Misawa, H Togashi, et al. Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma Gut, July 1, 2002; 51(1): 100 - 104. [Abstract] [Full Text] [PDF]

				P. Georgii-Hemming, T. Stromberg, E. T. Janson, M. Stridsberg, H. J. Wiklund, and K. Nilsson The Somatostatin Analog Octreotide Inhibits Growth of Interleukin-6 (IL-6)-Dependent and IL-6-Independent Human Multiple Myeloma Cell Lines Blood, March 1, 1999; 93(5): 1724 - 1731. [Abstract] [Full Text] [PDF]

				D SHOUVAL Octreotide in hepatocellular carcinoma Gut, March 1, 1998; 42(3): 316 - 318. [Full Text]

				E Kouroumalis, P Skordilis, K Thermos, A Vasilaki, J Moschandrea, and O N Manousos Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study Gut, March 1, 1998; 42(3): 442 - 447. [Abstract] [Full Text] [PDF]

				J. P. Holden, T. L. Butzow, G. A. Laughlin, M. Ho, A. J. Morales, and S. C. Yen Regulation of Insulin-Like Growth Factor Binding Protein-I During the 24-Hour Metabolic Clock and in Response to Hypoinsulinemia Induced by Fasting and Sandostatin in Normal Women Reproductive Sciences, January 1, 1995; 2(1): 38 - 44. [Abstract] [PDF]